Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study
Source: View publication →
In the phase II expansion of the OptimUM-01 study, the first-in-class targeted combination of darovasertib and crizotinib demonstrated a 34.1% objective response rate and a median overall survival of 21.1 months in treatment-naïve patients with metastatic uveal melanoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
Metastatic uveal melanoma is notorious for its dismal prognosis and limited treatment options, particularly for patients lacking the HLA-A*02:01 allele required for tebentafusp therapy. The robust objective response rate and a compelling median overall survival of 21.1 months observed with darovasertib and crizotinib establish this dual PKC and MET blockade as a highly promising, HLA-agnostic first-line strategy that warrants phase III evaluation.
Historical Context
Unlike cutaneous melanoma, uveal melanoma is biologically distinct, driven by GNAQ and GNA11 mutations in up to 95% of cases rather than BRAF mutations. These mutations constitutively activate protein kinase C (PKC). Uveal melanoma has historically responded poorly to standard immune checkpoint inhibitors. While the bispecific fusion protein tebentafusp recently improved overall survival, it is restricted to patients with a specific HLA type. OptimUM-01 provides proof-of-concept for a targeted, mechanism-based approach utilizing darovasertib, a novel PKC inhibitor, synergistically paired with the MET inhibitor crizotinib to overcome parallel signaling pathways.
Guided Discussion
High-yield insights from every perspective
Uveal melanoma has a distinct mutation profile compared to cutaneous melanoma. What is the mechanistic rationale for combining darovasertib and crizotinib in metastatic uveal melanoma, and which specific genetic mutations are targeted?
Key Response
Uveal melanomas are predominantly driven by GNAQ or GNA11 mutations, unlike BRAF mutations in cutaneous melanoma. These mutations activate the Protein Kinase C (PKC) pathway. Darovasertib is a PKC inhibitor. Crizotinib is a c-MET inhibitor. The combination targets both PKC and c-MET, overcoming potential resistance mediated by c-MET signaling bypass pathways often seen in metastatic uveal melanoma.
A treatment-naive patient presents with liver-predominant metastatic uveal melanoma. Based on the OptimUM-01 study, how does the efficacy of darovasertib plus crizotinib compare to the current standard-of-care tebentafusp, and what HLA testing considerations must be factored into this decision?
Key Response
Tebentafusp is currently the only FDA-approved therapy for metastatic uveal melanoma, but it is restricted to HLA-A*02:01-positive patients and has a low objective response rate of approximately 9 percent, despite an overall survival benefit. Darovasertib plus crizotinib showed an objective response rate of 34.1 percent and median overall survival of 21.1 months regardless of HLA status, providing a highly effective alternative, especially for HLA-A*02:01-negative patients who previously lacked targeted options.
The OptimUM-01 study demonstrates a robust objective response rate of 34.1 percent with darovasertib and crizotinib, yet the median overall survival of 21.1 months is comparable to that of tebentafusp, which has a much lower objective response rate. How do you reconcile the disparity between response rate and overall survival when comparing these two different therapeutic modalities?
Key Response
Tebentafusp is a T-cell engager immunotherapy, where overall survival benefits often decouple from traditional RECIST-based response rates due to delayed immune responses or stable disease. Conversely, darovasertib and crizotinib is a targeted kinase inhibitor combination, which typically induces rapid tumor shrinkage but may face acquired resistance that limits the tail of the survival curve. This highlights the limitations of using response rate as a surrogate for overall survival when comparing targeted therapies to immunotherapies.
Given the high objective response rate of the darovasertib and crizotinib combination in the first-line setting, how might this regimen be strategically sequenced or combined with liver-directed therapies for patients presenting with bulky hepatic metastases from uveal melanoma?
Key Response
Metastatic uveal melanoma has a strong tropism for the liver, and bulky disease is a major cause of mortality. A high response rate from systemic targeted therapy could be used as a cytoreductive neoadjuvant strategy to downstage hepatic tumors, potentially making them more amenable to liver-directed therapies such as radioembolization or resection, theoretically extending the 21.1-month median overall survival observed in the study.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The OptimUM-01 trial is a phase II expansion cohort without a randomized control arm. In a rare disease like metastatic uveal melanoma where standard-of-care is fragmented based on HLA status, what statistical designs could be utilized to rigorously benchmark the 21.1-month overall survival against historical controls?
Key Response
Due to the rarity of the disease and challenges of running large randomized controlled trials, researchers must rely on robust external control arms. Propensity score matching or inverse probability of treatment weighting using real-world data registries would be necessary to adjust for prognostic factors like tumor burden, LDH levels, and liver involvement to validate whether the 21.1-month survival represents a true statistical improvement over historical outcomes.
As a peer reviewer, how would you critically evaluate the safety profile and dose-interruptions reported in the OptimUM-01 study, and what missing patient-reported outcome data would you demand before endorsing this combination as a new first-line standard?
Key Response
Kinase inhibitor combinations often have overlapping toxicities, such as gastrointestinal events or transaminitis, leading to high rates of dose modifications. A reviewer must scrutinize the dose-intensity actually delivered versus planned. Without longitudinal patient-reported outcomes and quality of life metrics, it is impossible to determine if the extended survival and high response rate come at the cost of unacceptable chronic toxicity.
Currently, NCCN guidelines recommend tebentafusp as a category 1 preferred regimen for HLA-A*02:01-positive metastatic uveal melanoma, with clinical trials as a preferred option for others. How should the NCCN melanoma panel incorporate the darovasertib and crizotinib phase II data into the treatment algorithms, considering the strength of evidence?
Key Response
The guidelines should be updated to include darovasertib plus crizotinib as a preferred first-line systemic therapy for HLA-A*02:01-negative patients, where it fills an unmet need, likely as Category 2A based on Phase II data. For HLA-A*02:01-positive patients, it could be listed as an alternative first-line or preferred second-line option. The committee must weigh the Phase II nature of the data against the striking clinical activity, highlighting the need for a Phase III trial for Category 1 status.
Clinical Landscape
Noteworthy Related Trials
Phase II Selumetinib Trial
Tested
Selumetinib
Population
Patients with advanced uveal melanoma
Comparator
Chemotherapy (Temozolomide or Dacarbazine)
Endpoint
Progression-free survival
IMCgp100-202 Trial
Tested
Tebentafusp
Population
HLA-A*02:01-positive patients with metastatic uveal melanoma
Comparator
Investigator's choice (pembrolizumab, ipilimumab, or dacarbazine)
Endpoint
Overall survival
Phase II Ipi/Nivo MUM Trial
Tested
Nivolumab plus Ipilimumab
Population
Patients with metastatic uveal melanoma
Comparator
Single-arm (no comparator)
Endpoint
Overall response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis